J

Jackson Heart Clinic | Jackson, MS

Research site
(Unclaimed)
Location
970 Lakeland Dr Suite 61, Jackson, Mississippi, United States of America
Site insights

Top conditions

Atrial Fibrillation (11 trials)

Heart Failure (8 trials)

Coronary Artery Disease (4 trials)

Peripheral Arterial Disease (4 trials)

Peripheral Vascular Diseases (3 trials)

Top treatments

aspirin
sodium
prasugrel
Ziltivekimab
Vitamin K
DAPT
Edoxaban
Inclisiran
clopidogrel

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

8 of 39
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling
Atrial Fibrillation
Stroke
Drug: Non-Vitamin K Oral Antagonists
Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Begins enrollment in 2 months
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Rest...

Enrolling
Dilated Cardiomyopathy
Heart Failure With Reduced Ejection Fraction (HFrEF)
Device: AccuCinch Ventricular Restoration System
Drug: Guideline-Directed Medical Therapy

The purpose of the Diamond-AF II study is to establish the safety and effectiveness of the DiamondTemp Ablation System for the treatment of drug refr...

Active, not recruiting
Atrial Fibrillation
Persistent Atrial Fibrillation
Device: Radiofrequency Ablation

The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when c...

Enrolling
Cryptogenic Stroke
Patent Foramen Ovale
Device: Encore PFO closure device
Device: FDA-approved PFO closure device

The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everoli...

Active, not recruiting
Critical Limb Ischemia (CLI)
Device: Percutaneous Transluminal Angioplasty (PTA) Device
Device: Esprit BTK Device

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Abbott logo

Abbott (18 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems